Jonathan Chang
Stock Analyst at Leerink Partners
(0.81)
# 2,720
Out of 4,479 analysts
83
Total ratings
28.36%
Success rate
-19.23%
Average return
Main Sectors:
Top Industries:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $34.80 | +112.64% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $5.24 | +109.92% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $16.80 | +203.57% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $6 → $5 | $0.80 | +525.00% | 10 | Jan 10, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $34 | $8.37 | +306.21% | 9 | Dec 7, 2022 | |
| CALA Calithera Biosciences | Downgrades: Market Perform | $18 → $2 | $0.01 | +15,900.00% | 5 | Nov 15, 2022 | |
| GMAB Genmab | Maintains: Market Perform | $31 → $33 | $24.90 | +32.53% | 9 | Nov 10, 2022 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $19.81 | +152.40% | 4 | Aug 22, 2022 | |
| VINC Vincerx Pharma | Maintains: Outperform | $6 → $5 | $0.74 | +578.43% | 5 | Aug 12, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $37.38 | -19.74% | 3 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $4.10 | +192.68% | 5 | Aug 9, 2022 | |
| MRSN Mersana Therapeutics | Maintains: Outperform | $13 → $14 | $1.86 | +652.69% | 5 | Aug 9, 2022 | |
| IMTX Immatics | Maintains: Outperform | $25 → $26 | $12.02 | +116.31% | 5 | Jun 3, 2022 | |
| ZLAB Zai Lab | Maintains: Outperform | $101 → $95 | $17.37 | +446.92% | 8 | May 11, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Market Perform | $2 → $3 | $1.05 | +185.71% | 6 | May 9, 2022 | |
| KURA Kura Oncology | Maintains: Outperform | $41 → $28 | $20.58 | +36.05% | 3 | Feb 25, 2022 | |
| XNCR Xencor | Maintains: Outperform | n/a | $18.26 | - | 3 | Aug 5, 2021 |
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $34.80
Upside: +112.64%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $5.24
Upside: +109.92%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $16.80
Upside: +203.57%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $6 → $5
Current: $0.80
Upside: +525.00%
Replimune Group
Dec 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $8.37
Upside: +306.21%
Calithera Biosciences
Nov 15, 2022
Downgrades: Market Perform
Price Target: $18 → $2
Current: $0.01
Upside: +15,900.00%
Genmab
Nov 10, 2022
Maintains: Market Perform
Price Target: $31 → $33
Current: $24.90
Upside: +32.53%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $19.81
Upside: +152.40%
Vincerx Pharma
Aug 12, 2022
Maintains: Outperform
Price Target: $6 → $5
Current: $0.74
Upside: +578.43%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $37.38
Upside: -19.74%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $4.10
Upside: +192.68%
Mersana Therapeutics
Aug 9, 2022
Maintains: Outperform
Price Target: $13 → $14
Current: $1.86
Upside: +652.69%
Immatics
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $12.02
Upside: +116.31%
Zai Lab
May 11, 2022
Maintains: Outperform
Price Target: $101 → $95
Current: $17.37
Upside: +446.92%
Adaptimmune Therapeutics
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $1.05
Upside: +185.71%
Kura Oncology
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $20.58
Upside: +36.05%
Xencor
Aug 5, 2021
Maintains: Outperform
Price Target: n/a
Current: $18.26
Upside: -